Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels

ELGART, JORGE F.; SILVESTRINI, CONSTANZA; PRESTES, MARIANA; GONZALEZ, LORENA; RUCCI, ENZO; GAGLIARDINO, JUAN J.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

WILEY-BLACKWELL PUBLISHING, INC

Año: 2019 vol. 73

1368-5031

Aims: To examine the relationship between costs of hyperglycaemia drug treatment and glycemic control amongst people with type 2 diabetes (T2D). Methods: This observational study utilised data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: on target (OT; HbA1c ≤ 7%), and not on target (NOT; HbA1c > 7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycaemia treatment. Monthly expenditure on drugs was estimated by micro-costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycaemia treatment and HbA1c values. Results: In total, 48.9% of the participants have HbA1c OT values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycaemia drugs treatment was significant associated with glycemic control (OR: 0.705), diabetes duration (OR: 1.017), systolic blood pressure (OR: 1.006) and treatment of T2D (OR: 2.622). Conclusions: HbA1c NOT significantly increases drugs monthly cost of hyperglycaemia treatment in people with T2D in a country with an emerging market economy.